DENVER, Colo. (247marketnews.com) -- Werewolf Therapeutics (NASDAQ:HOWL) is effectively rewriting its investment story. The company has agreed to merge with privately held Ambros Therapeutics in an all-stock transaction that will bring late-stage drug candidate neridronate into a Nasdaq-listed vehicle, while simultaneously securing an oversubscribed $150 million private placement from a heavyweight group of healthcare investors. The combined company is expected to operate as Ambros Therapeutics and trade under NASDAQ:AMBX, subject to closing conditions.
The centerpiece is CRPS-RISE, an ongoing Phase 3 trial testing neridronate in patients with warm-phase Complex Regional Pain Syndrome Type 1 (CRPS-1), a severely debilitating condition for which Ambros says there are currently no FDA-approved medicines. The FDA has granted neridronate Breakthrough Therapy, Fast Track and Orphan Drug designations, while Ambros says discussions with the FDA support the possibility that one successful pivotal trial could underpin a potential approval. The first patient was dosed in June, putting the program firmly into the clinical countdown, with topline results anticipated in 2028.
The financing is arguably just as important as the merger. Ambros says the $150 million raise is expected to provide funding through CRPS-RISE topline results and a planned NDA submission, with cash runway extending into the first half of 2029. The investor syndicate includes RA Capital Management and Janus Henderson Investors as co-leads, alongside a long list of healthcare-focused investors. Ambros CEO Jay Hagan called the deal a “transformative announcement,” while Werewolf CEO Daniel Hicklin said the potential of neridronate to deliver a meaningful treatment for CRPS-1 was “very compelling.”
For existing NASDAQ: HOWL shareholders, however, this is not simply a drug-development victory lap. The transaction implies a $500 million value for Ambros before the financing, versus an implied $47.5 million value for Werewolf, with pre-merger Werewolf holders expected to own approximately 6.8% of the combined company, excluding private-placement investors. The deal also marks a dramatic strategic pivot for Werewolf, which had been evaluating strategic alternatives and had substantially reduced its workforce earlier this year.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.